Skip to main content
Premium Trial:

Request an Annual Quote

Genes2Me Obtains CE Marking for Clinical Sequencing Panels

NEW YORK – Indian genetic testing company Genes2Me said on Wednesday that it has obtained CE marking for more than 25 next-generation sequencing-based panels for oncology, pharmacogenomics, and hereditary diseases.

The panels were designed and have been validated for all NGS platforms from Illumina, Thermo Fisher Scientific, and MGI and come with automated data analysis pipelines.

One of the company’s offerings is a pan-cancer panel that covers 525 genes. Starting with 50 ng of nucleic acid, the firm said, the panel can detect single nucleotide variants, insertions and deletions, copy number variants, microsatellite instability, fusions, splice variants, and oncogenic viruses, as well as measure tumor mutation burden in one assay.

In addition, the company offers liquid biopsy NGS panels for colon, breast, and lung cancer; pharmacogenomics panels that help with the selection and dosage of drugs; a clinical exome sequencing extended panel; and targeted panels for neuromuscular diseases, epilepsy, Alzheimer's disease, Parkinson's disease, and dementia.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.